These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 8191763

  • 21. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS.
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [Abstract] [Full Text] [Related]

  • 24. Treatment of progressive metastatic prostate cancer.
    Dawson NA.
    Oncology (Williston Park); 1993 May; 7(5):17-24, 27; discussion 27-9. PubMed ID: 8512779
    [Abstract] [Full Text] [Related]

  • 25. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
    Moul JW, Zlotta AR.
    BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
    [No Abstract] [Full Text] [Related]

  • 26. Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy.
    Lee EC, Tenniswood MP.
    J Cell Biochem; 2004 Mar 01; 91(4):662-70. PubMed ID: 14991758
    [Abstract] [Full Text] [Related]

  • 27. [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation].
    Akaza H, Labrie F, Namiki M.
    Gan To Kagaku Ryoho; 2007 Apr 01; 34(4):657-69. PubMed ID: 17431361
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Taplin ME.
    Nat Clin Pract Oncol; 2007 Apr 01; 4(4):236-44. PubMed ID: 17392714
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9.
    Ragavan N, Singh PB, Martin FL, Baird AD.
    Eur Urol; 2009 Feb 01; 55(2):e43-4. PubMed ID: 18771846
    [No Abstract] [Full Text] [Related]

  • 36. [Therapeutic implications of the revised concept of hormone-refractory metastatic prostate cancer].
    Paule B.
    Prog Urol; 2004 Dec 01; 14(6):1119-24. PubMed ID: 15751404
    [Abstract] [Full Text] [Related]

  • 37. Current status and prospects of androgen depletion therapy for prostate cancer.
    Akaza H.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 01; 22(2):293-302. PubMed ID: 18471787
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Overview of current status of total androgen deprivation in metastasized prostate cancer.
    Debruyne FM, Witjes WP.
    Eur Urol; 1993 Apr 01; 24 Suppl 2():67-71. PubMed ID: 8262129
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.